# A Phase IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis in Patients With Chronic Hepatitis B.

> **NCT07412236** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Beijing Continent Pharmaceutical Co, Ltd.** · enrollment: 1208 (estimated)

## Conditions studied

- Liver Fibrosis
- Liver Fibrosis in Chronic Hepatitis B

## Interventions

- **DRUG:** Hydronidone (270mg)
- **DRUG:** Hydronidone (Placebo Group)

## Key facts

- **NCT ID:** NCT07412236
- **Lead sponsor:** Beijing Continent Pharmaceutical Co, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-30
- **Primary completion:** 2028-12-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 1208 (ESTIMATED)
- **Last updated:** 2026-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07412236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07412236, "A Phase IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis in Patients With Chronic Hepatitis B.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07412236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*